NCT01282801已完成1 期
Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsules in Healthy Subjects Under Fed Conditions.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Cmax of Venlafaxine.
研究概览
简要总结
The objective of this study was to compare the rate and extent of absorption of venlafaxine hydrochloride 150 mg extended-release capsules (test) versus Effexor® XR (reference) administered as 1 x 150 mg extended-release capsule under fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Members of the community at large.
- •Subjects will be females and/or males, non-smokers, 18 years of age and older.
- •Female subjects will be post-menopausal or surgically sterilized.
排除标准
- •Clinically significant illnesses within 4 weeks of the administration of study medication.
- •Clinically significant surgery within 4 weeks prior to the administration of the study medication.
- •Any clinically significant abnormality found during medical screening.
- •Any history or presence of significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
- •History or presence of any clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
- •Subjects with raised intra-ocular pressure or at risk of acute narrow angle glaucoma.
- •Subjects predisposed to bleeding of the skin and mucous membrane.
- •Subjects with a history of seizures.
- •Any reason which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study.
- •Abnormal laboratory tests judged clinically significant.
- •Positive urine drug screen at screening.
- •Positive testing for hepatitis B, hepatitis C, or HIV at screening.
- •ECG abnormalities (clinically significant) or vital sign abnormalities at screening.
- •Subjects with BMI > 30.
- •History of significant alcohol abuse within six months of screening visit or any indication of the regular use of more than fourteen units of alcohol per week (1 unit equals 150 mL of wine, 360 mL of beer, or 45 mL of alcohol 45%).
- •History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (cocaine, PCP, crack) within 1 year of the screening visit.
- •Any food allergy, intolerance, restriction, or special diet that, in the opinion of the medical sub-investigator, contraindicates the subject's participation in the study.
- •History of allergic reactions to venlafaxine hydrochloride.
- •History of allergic reactions to heparin.
- •Use of any drugs know to induce or inhibit hepatic drug metabolism, use of an investigational drug, or participation in an investigational study within 30 days prior to administration of the study medication.
- •Use of prescription medication within 14 days prior to administration of the study medication or over-the-counter products within 7 days prior to the administration of study medication, except for topical products without systemic absorption.
- •Subjects who have had a depot injection or an implant of any drug 3 months prior to administration of the study medication.
- •Donation of plasma (500 mL) within 7 days of Period I dosing. Donation or loss of whole blood prior to administration of the study medication as follows:
- •less than 300 mL of whole blood within 30 days or
- •300 mL to 500 mL of whole blood within 45 days or
- •more than 500 mL of whole blood within 56 days.
- •Positive alcohol breath test at screening.
- •Subjects who have used tobacco in any form within the 90 days preceding study drug administration.
- •Subjects who have consumed food or beverages containing grapefruit within 7 days prior to administration of the study medication.
- •Intolerance to venipunctures.
- •Additional exclusion criteria for females only:
- •Breastfeeding subjects.
- •Positive urine pregnancy test at screening.
研究组 & 干预措施
Investigational Test Product
Experimental
Venlafaxine Hydrochloride 150 mg Extended-Release Capsules
干预措施: Venlafaxine Hydrochloride (Drug)
Reference Listed Drug
Active Comparator
Effexor® XR 150 mg Extended-Release Capsules
干预措施: Effexor® XR (Drug)
结局指标
主要结局
Cmax of Venlafaxine.
时间窗: Blood samples collected over a 36 hour period.
Bioequivalence based on Venlafaxine Cmax (maximum observed concentration of drug substance in plasma).
AUC0-t of Venlafaxine.
时间窗: Blood samples collected over a 36 hour period.
Bioequivalence based on Venlafaxine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
AUC0-inf of Venlafaxine.
时间窗: Blood samples collected over a 36 hour period.
Bioequivalence based on Venlafaxine AUC0-inf (area under the concentration-time curve from time zero to infinity).
次要结局
- Cmax of O-Desmethylvenlafaxine.(Blood samples collected over a 36 hour period.)
- AUC0-t of O-Desmethylvenlafaxine.(Blood samples collected over a 36 hour period.)
- AUC0-inf of O-Desmethylvenlafaxine.(Blood samples collected over a 36 hour period.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting ConditionsHealthyNCT01260896Teva Pharmaceuticals USA24
已完成
1 期
Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle StudyHealthyNCT01282814Teva Pharmaceuticals USA24
已完成
1 期
Venlafaxine 25 mg Tablets Under Non-Fasting ConditionsHealthyNCT00834249Teva Pharmaceuticals USA18
已完成
1 期
Venlafaxine 25 mg Tablets Under Fasting ConditionsHealthyNCT00834964Teva Pharmaceuticals USA30
已完成
1 期
Valacyclovir 1000 mg Tablet Under Fed ConditionsHealthyNCT01149460Teva Pharmaceuticals USA36